Biohaven

Historical price data

Biohaven is a clinical-stage biopharmaceutical company with a mission to discover, develop, and commercialize life-changing therapies for severe diseases. Its most significant achievement was the discovery, approval, and subsequent $11.6 billion divestiture of its CGRP migraine franchise (Nurtec® ODT, Zavzpret®) to Pfizer in 2022, which provided substantial capital to fund its next-generation pipeline. The company's strategy is to leverage its proven drug development expertise and three proprietary technology platforms—glutamate modulation, myostatin inhibition, and Kv7 targeting—to build a diversified portfolio targeting large neurological and rare disease markets. Biohaven's 'patient-first' culture and non-hierarchical structure are designed to drive urgency and efficiency in clinical execution.

Biohaven leverages three proprietary drug development platforms: a Glutamate Modulation platform for neurological/psychiatric disorders, a Myostatin Inhibition platform for muscle-wasting and metabolic diseases, and a Kv7 Ion Channel Targeting platform for neuronal hyperexcitability conditions like epilepsy.

Biohaven competes in crowded and competitive therapeutic areas. In obesity, it must demonstrate added value alongside dominant GLP-1 agonists. In epilepsy and OCD, it faces numerous approved and developmental therapies. Its differentiation lies in novel mechanisms (glutamate, myostatin, Kv7) targeting specific patient subpopulations with high unmet need.